ArticleThe Lancet. Respiratory medicine2018
Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study.
Article in The Lancet. Respiratory medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 4 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- ADRB2 haplotypes and asthma exacerbations in children and young adults: An individual participant data meta-analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021Pooled it
- Genome-wide association studies of exacerbations in children using long-acting beta2-agonists.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2021Pooled it
- Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation.The pharmacogenomics journal · 2020Pooled it
- Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management.American journal of respiratory and critical care medicine · 2020Pooled it
- Economic impact of steroid-induced comorbidities in severe asthma: a SHARP CRC simulation.ERJ open research · 2025Article
- Endotype-driven decisions in choosing a biologic for airway diseases.Frontiers in allergy · 2025Review
- Predicting Risk of Morbidities Associated with Oral Corticosteroid Prescription for Asthma.Pragmatic and observational research · 2025Article
- Glucocorticoid treatment and adrenal suppression in children: current view and open issues.Journal of endocrinological investigation · 2025Review
- Defining the Differential Corticosteroid Response Basis from Multiple Omics Approaches.International journal of molecular sciences · 2024Review
- Current Challenges and Future Directions in the Assessment of Glucocorticoid Status.Endocrine reviews · 2024Review
- Urine metabolomics signature reveals novel determinants of adrenal suppression in children taking inhaled corticosteroids to control asthma symptoms.Immunity, inflammation and disease · 2024Article
- Iatrogenic adrenal insufficiency in adults.Nature reviews. Endocrinology · 2024Review
- Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History.Biomolecules · 2024Review
- Pharmacogenomics: current status and future perspectives.Nature reviews. Genetics · 2023Review
- Long-Term Usage of Oral Glucocorticoids Leading to Adrenal Insufficiency: A Comprehensive Review of the Literature.Cureus · 2023Review
- Platelet-derived growth factor D expression in adrenal cells is modulated by corticosteroids: putative role in adrenal suppression.Pediatric research · 2023Article
- Article
- High miR203a-3p and miR-375 expression in the airways of smokers with and without COPD.Scientific reports · 2022Article
- Inhaled corticosteroid use for asthma is linked to adrenal suppression.Nature medicine · 2022Article
- Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma.Nature medicine · 2022Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
19 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundA serious adverse effect of corticosteroid therapy is adrenal suppression. Our aim was to identify genetic variants affecting susceptibility to corticosteroid-induced adrenal suppression.
methodsWe enrolled children with asthma who used inhaled corticosteroids as part of their treatment from 25 sites across the UK (discovery cohort), as part of the Pharmacogenetics of Adrenal Suppression with Inhaled Steroids (PASS) study. We included two validation cohorts, one comprising children with asthma (PASS study) and the other consisting of adults with chronic obstructive pulmonary disorder (COPD) who were recruited from two UK centres for the Pharmacogenomics of Adrenal Suppression in COPD (PASIC) study. Participants underwent a low-dose short synacthen test. Adrenal suppression was defined as peak cortisol less than 350 nmol/L (in children) and less than 500 nmol/L (in adults). A case-control genome-wide association study was done with the control subset augmented by Wellcome Trust Case Control Consortium 2 (WTCCC2) participants. Single nucleotide polymorphisms (SNPs) that fulfilled criteria to be advanced to replication were tested by a random-effects inverse variance meta-analysis. This report presents the primary analysis. The PASS study is registered in the European Genome-phenome Archive (EGA). The PASS study is complete whereas the PASIC study is ongoing.
findingsBetween November, 2008, and September, 2011, 499 children were enrolled to the discovery cohort. Between October, 2011, and December, 2012, 81 children were enrolled to the paediatric validation cohort, and from February, 2010, to June, 2015, 78 adults were enrolled to the adult validation cohort. Adrenal suppression was present in 35 (7%) children in the discovery cohort and six (7%) children and 17 (22%) adults in the validation cohorts. In the discovery cohort, 40 SNPs were found to be associated with adrenal suppression (genome-wide significance p<1 × 10
interpretationOur findings suggest that genetic variation in the PDGFD gene locus increases the risk of adrenal suppression in children and adults who use corticosteroids to treat asthma and COPD, respectively.
fundingDepartment of Health Chair in Pharmacogenetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.